KDR - kinase insert domain receptor Gene

Also Known as FLK/KDR

Species: Oryctolagus cuniculus

Gene Type: protein coding
Gene ID: 100008607

About KDR

Chromosome 15: 93,608,315-93,652,418 forward strand.OryCun2.0:CM000804.1

This gene has 1 transcript (splice variant), 199 orthologues and 56 paralogues.

KDR Products (1)

mRNA Protein Name
NM_001195670.1 NP_001182599.1 vascular endothelial growth factor receptor 2 precursor

KDR Protein Structure

Ig

Ig: cl11960 (223 - 325)

Ig

Ig: cd00096 (241 - 245)

Ig

Ig: cd00096 (256 - 260)

Ig

Ig: cd00096 (289 - 293)

Ig

Ig: cd00096 (303 - 308)

Ig

Ig: cd00096 (316 - 319)

Ig

Ig: cl11960 (328 - 416)

Ig

Ig: cd00096 (347 - 351)

Ig

Ig: cd00096 (360 - 364)

Ig

Ig: cd00096 (380 - 384)

Ig

Ig: cd00096 (394 - 399)

Ig

Ig: cd00096 (409 - 412)

Ig_3

Ig_3: pfam13927 (550 - 643)

I-set

I-set: pfam07679 (666 - 753)

Ig

Ig: cd00096 (683 - 687)

Ig

Ig: cd00096 (696 - 700)

Ig

Ig: cd00096 (719 - 723)

Ig

Ig: cd00096 (733 - 738)

VEGFR-2_TMD

VEGFR-2_TMD: pfam17988 (758 - 792)

PTKc_VEGFR2

PTKc_VEGFR2: cd05103 (825 - 1166)

  • 0
  • 300
  • 600
  • 900
  • 1200
  • 1356 a.a.
Protein Preferred Names Protein Names

vascular endothelial growth factor receptor 2

  • VEGF receptor-2/Flk-1

  • kinase insert domain receptor (a type III receptor tyrosine kinase)

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (6)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-10260 Vandetanib 99.85% Yes
HY-112306 Ripretinib 98.90% Yes
HY-14914 Azilsartan 99.68% Unkown
HY-10330A Toceranib phosphate Inhibitor 99.23% Unkown
HY-10260B Vandetanib hydrochloride / Unkown
HY-10260A Vandetanib trifluoroacetate / Unkown

Clinical Phase

Bioactive Molecules (14)
Cat. No. Product Name Effect
Purity Phase
HY-50751 Linifanib 99.39% Phase 3
HY-10205 Cediranib 99.87% Phase 3
HY-10203 Vatalanib Inhibitor 99.93% Phase 3
HY-12018 Vatalanib dihydrochloride 99.68% Phase 3
HY-13049 Cediranib maleate 99.95% Phase 3
HY-12018A Vatalanib hydrochloride Inhibitor / Phase 3
HY-110272 Vatalanib succinate Inhibitor / Phase 3
HY-10374 Semaxinib Inhibitor 99.92% Phase 2
HY-13024 Rebastinib 99.84% Phase 2
HY-10338 Foretinib Inhibitor 99.45% Phase 2
HY-10987A ENMD-2076 99.99% Phase 2
HY-10987 ENMD-2076 Tartrate 99.66% Phase 2
HY-10204 OSI-930 98.33% Phase 1
HY-100315 XL 999 Inhibitor 99.01% Phase 1
Bioactive MoleculesInhibitory Antibodies (2)
Cat. No. Product Name Effect
Purity Phase
HY-P99768 Olinvacimab Inhibitor 95.00% Phase 2
HY-P991419 MSB-0254 Inhibitor / Phase 1

Pre-clinical Phase

Bioactive Molecules (59)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-12299 WH-4-023 Inhibitor 99.87% Unkown
HY-151361 AMPK-IN-3 Inhibitor 98.51% Unkown
HY-W062835 CGP77675 Inhibitor 99.46% Unkown
HY-10330 Toceranib Inhibitor 97.41% Unkown
HY-144707 AK-778-XXMU 99.96% Unkown
HY-P1663 ATWLPPR Peptide Inhibitor 99.63% Unkown
HY-18302 c-Kit-IN-5-1 Inhibitor 98.03% Unkown
HY-W002616 5-Bromoindolin-2-one 99.50% Unkown
HY-13838 PLX647 Inhibitor 99.74% Unkown
HY-15814 HG-7-85-01 98.14% Unkown
HY-13785 ZM 306416 Inhibitor 99.80% Unkown
HY-P5438 Srctide Substrate 99.71% Unkown
HY-101219 VEGFR-IN-1 Inhibitor 99.07% Unkown
HY-125741 GW768505A free base Inhibitor 99.26% Unkown
HY-10517A (Z)-Orantinib Inhibitor 99.44% Unkown
HY-15769 WHI-P180 Inhibitor 99.84% Unkown
HY-132135 (1E)-CFI-400437 dihydrochloride Inhibitor 98.08% Unkown
HY-133551 WF-47-JS03 Inhibitor 99.63% Unkown
HY-119757 Tyrphostin AG1433 Inhibitor 99.08% Unkown
HY-RS07226 KDR Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-148742 RET-IN-21 Inhibitor 97.00% Unkown
HY-RS07227 Kdr Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-118105 RK-20448 Inhibitor 99.38% Unkown
HY-50751G Linifanib (GMP) Inhibitor / Unkown
HY-100824 PP2 Analog Inhibitor / Unkown
HY-10260S Vandetanib-d6 / Unkown
HY-10260S1 Vandetanib-d4 / Unkown
HY-10260S2 Vandetanib-13C6 / Unkown
HY-10330S Toceranib-d8 Inhibitor 99.08% Unkown
HY-116190 CFI-401870 Inhibitor / Unkown
HY-117733 Zerumin A Inhibitor / Unkown
HY-120214 TAS05567 Inhibitor / Unkown
HY-123586 L-783277 Inhibitor / Unkown
HY-13838A PLX647 dihydrochloride Inhibitor / Unkown
HY-146369 PROTAC VEGFR-2 degrader-2 Degrader / Unkown
HY-14979 ML786 Inhibitor / Unkown
HY-14979A ML786 dihydrochloride Inhibitor / Unkown
HY-15334 CEP-5214 Inhibitor / Unkown
HY-168114 Multi-kinase inhibitor 3 Inhibitor / Unkown
HY-168115 Multi-kinase inhibitor 4 Inhibitor / Unkown
HY-172487 DSPE-PEG1000-K237 / Unkown
HY-172488 DSPE-PEG2000-K237 / Unkown
HY-172488A DSPE-PEG3400-K237 / Unkown
HY-172489 DSPE-PEG5000-K237 / Unkown
HY-175477 UNC9750 Inhibitor / Unkown
HY-18318 Takeda-6D Inhibitor 99.41% Unkown
HY-18692 Multi-kinase-IN-12 Inhibitor / Unkown
HY-N16797 Sanggenol C / Unkown
HY-RS07228 Kdr Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-W062835A CGP77675 hydrate Inhibitor / Unkown
HY-W701071 Vatalanib-d4 / Unkown
HY-110045 ZM-306416 hydrochloride Inhibitor / Unkown
HY-119757A Tyrphostin AG1433 hydrochloride Inhibitor / Unkown
HY-149451 SYHA1815 Inhibitor / Unkown
HY-15769A WHI-P180 hydrochloride Inhibitor / Unkown
HY-174593 Human KDR mRNA / Unkown
HY-183616 VEGFR-2-IN-87 Inhibitor / Unkown
HY-N10379 19-epi-Scholaricine 99.14% Unkown
HY-101628 VEGFR-2-IN-9 Inhibitor / Unkown
Bioactive MoleculesInhibitory Antibodies (6)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-P991141 Inlecitug Ligand 98.62% Unkown
HY-P991689 Girancitug Inhibitor 98.80% Unkown
HY-P990318 Alacizumab Inhibitor / Unkown
HY-P990542 Anti-VEGFR2/KDR/CD309 Antibody Inhibitor / Unkown
HY-P990543 Anti-VEGFR2/KDR/CD309 Antibody (AT001) Inhibitor / Unkown
HY-P991420 UB-925 Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens KDR NCBI NCBI:3791